home / stock / oncs / oncs news

ONCS News and Press, OncoSec Medical Incorporated From 04/03/23

Stock Information
Company Name: OncoSec Medical Incorporated
Stock Symbol: ONCS
Market: NASDAQ
Menu
ONCS ONCS Quote ONCS Short ONCS News ONCS Articles ONCS Message Board
Get ONCS Alerts

News, Short Squeeze, Breakout and More Instantly...
ONCS - VNET, VTSI and PLSE among mid-day movers

2023-04-03 13:28:55 ET Gainers: Guardforce AI ( GFAI ) +126% . Nogin ( NOGN ) +110% . Harbor Custom Development ( HCDI ) +33% . Indonesia Energy Corporation ( INDO ) +30% . Pulse Biosciences ( PLSE ) +29% . Barnwell Industrie...
ONCS - Heska, Heron top healthcare gainers; OncoSec, Ascendis lead losers' pack

2023-04-03 10:02:08 ET Gainers: Heska ( HSKA ) +20% . Heron Therapeutics ( HRTX ) +19% . InterCure ( INCR ) +17% . Innate Pharma ( IPHA ) +15% . Apellis Pharmaceuticals ( APLS ) +14% . Losers: OncoSec Medical ( ONCS...

ONCS - OncoSec crashes ~60% after TAVO-EP, Keytruda combo fails phase 2 skin cancer trial

2023-04-03 08:48:27 ET OncoSec Medical's ( NASDAQ: ONCS ) TAVO-EP in combination with Merck's ( NYSE: MRK ) Keytruda did not meet the main goal of overall response rate (ORR) in phase 2 trial to treat patients with a type of skin cancer. The mid-stage study, dubbed&...

ONCS - NAT, FRO and UBS among pre-market losers

2023-04-03 08:16:44 ET OncoSec Medical ( ONCS ) -62% clinical data of the KEYNOTE-695 trial assessing TAVO EP in combination with KEYTRUDA (pembrolizumab) in patients with advanced melanoma refractory to anti-PD-1 treatment. Ascendis Pharma ( ASND ) -38% after FD...
ONCS - OncoSec Announces Clinical Data of the KEYNOTE-695 Trial Assessing TAVO(TM)-EP in Combination with KEYTRUDA® (pembrolizumab) in Patients with Advanced Melanoma Refractory to anti-PD-1 Treatment

OncoSec Announces Clinical Data of the KEYNOTE-695 Trial Assessing TAVO™-EP in Combination with KEYTRUDA® (pembrolizumab) in Patients with Advanced Melanoma Refractory to anti-PD-1 Treatment PR Newswire EWING, N.J. and SAN DIEGO , April 3, 2023 /P...

ONCS - THMO, CNET and LOOP among mid-day movers

2023-03-28 13:10:56 ET Gainers: Biomea Fusion ( BMEA ) +73% . Oscar Health ( OSCR ) +72% . Viking Therapeutics ( VKTX ) +63% . Pyxis Oncology ( PYXS ) +46% . Bird Global ( BRDS ) +44% . NaaS Technology ( NAAS ) +26% ....

ONCS - Biomea, Oscar top healthcare gainers; Monopar, OncoSec lead losers' pack

2023-03-28 10:00:38 ET Gainers: Biomea Fusion ( BMEA ) +56% . Oscar Health ( OSCR ) +54% . Viking Therapeutics ( VKTX ) +51% . Intra-Cellular Therapies ( ITCI ) +20% . Guardion Health Sciences ( GHSI ) +17% . Losers...
ONCS - iHeartMedia, Invesco Mortgage Capital, FiscalNote among premarket losers' pack

2023-03-28 08:31:04 ET Monopar Therapeutics MNPR -50% as Validive program gets axed after trial failure . WiSA Technologies WISA -28% after proposes securities offering . OncoSec Medical ( ONCS ) -25% . Allarity Therapeutics ALLR -18% amid enr...

ONCS - IOVA, MQ and ONCS are among pre market gainers

2023-03-27 08:52:49 ET First Citizens BancShares ( FCNCA ) +39% deal for First Citizens to buy Silicon Valley Bank. First Republic Bank ( FRC ) +24% inks deal for First Citizens to buy Silicon Valley Bank. Baudax  ( BXRX ) +26% Announces Posi...

ONCS - BridgeBio, Armata top healthcare gainers; Aclaris, Adaptimmune among losers

2023-03-06 10:00:19 ET Gainers: BridgeBio Pharma ( BBIO ) +67% . Armata Pharmaceuticals ( ARMP ) +23% . TCR2 Therapeutics ( TCRR ) +21% . Euda Health ( EUDA ) +12% . Kala Pharmaceuticals ( KALA ) +16% . Losers: Aclaris...
Previous 10 Next 10